Oral Semaglutide
60 articles on Oral Semaglutide, written by Shotlee and medically reviewed for clinical accuracy.
Wegovy Weight Loss Pill Warning: Make Three Changes Now
The new oral Wegovy formulation has arrived, but hair shedding concerns remain. Discover the science behind the risk and three actionable lifestyle changes to protect your hair health while on semaglutide.
8 min read
New Weight Loss Pill Beats Oral Ozempic in Major Clinical Trial
A recent Phase 3 clinical trial indicates that orforglipron offers superior blood sugar control and weight loss compared to oral semaglutide, though side effects remain a consideration.
9 min read
Ozempic's Oral Twin: A Needle-Free Weight Loss Revolution Arrives?
A new era in weight management may be dawning as an oral medication, mirroring the efficacy of popular injectables like Ozempic, is poised for approval. This development promises a more accessible and convenient path to weight loss for millions.
7 min read
Eli Lilly's Foundayo: A New Daily Pill Outperforming Oral Semaglutide
A groundbreaking Phase 3 trial reveals that Eli Lilly's new daily oral medication, orforglipron (Foundayo), demonstrates superior efficacy in lowering blood sugar and promoting weight loss compared to existing oral semaglutide treatments for individuals with Type 2 diabetes. This development marks a significant step forward in non-injectable peptide therapies for metabolic health.
6 min read
Wegovy Pill Arrives in the UK: A New Era for Weight Management?
The UK has officially approved a pill version of the popular Wegovy weight-loss drug, marking a significant advancement in accessible obesity treatment. This development offers a convenient alternative to weekly injections for many.
6 min read
Oral Wegovy's Record-Breaking Launch: The New Era of Needle-Free Weight Loss
Novo Nordisk's Wegovy oral formulation has achieved unprecedented prescription rates, marking a pivotal shift in obesity care and intensifying competition with Eli Lilly.
8 min read
Wegovy Pill Launch: Why 80% of Patients Are Choosing Oral Semaglutide
The launch of the Wegovy pill marks a pivotal shift in obesity treatment. With 80% of new users being first-time patients, oral semaglutide is overcoming historical barriers to care.
9 min read
Beyond the Needle: New Oral Semaglutide Tech Could Change Weight Loss Forever
Duke University researchers have developed a novel oral delivery system for GLP-1 medications that protects peptides from stomach acid, potentially eliminating the need for injections.
8 min read
Wegovy Pill Arrives: A New Era for Oral Weight Management in the UAE
Novo Nordisk's revolutionary Wegovy pill (oral semaglutide) is set to transform weight management in the UAE. Discover the details of its early access launch, clinical benefits, and how it integrates into advanced care pathways.
7 min read
Beyond Weight Loss: The Expanding Horizon of GLP-1 Therapies
GLP-1 agonists, famously known for Ozempic and Wegovy, are making waves beyond their initial indications. While weight loss and diabetes management remain key, researchers are uncovering a broader therapeutic potential for these powerful peptide therapies.
8 min read
Beyond the Injection: The Future of GLP-1 Therapies
GLP-1 receptor agonists have revolutionized weight loss and diabetes management, but researchers are continuously seeking ways to enhance their delivery. This article delves into cutting-edge advancements, from nanocarriers to microneedles, aiming to make these powerful therapies more effective, tolerable, and convenient.
7 min read
Oral GLP-1s Enter the Ring: Early Trends Favoring Foundao Over Wegovy's Pill
The landscape of weight loss treatments is rapidly changing with the introduction of oral GLP-1 medications. This article delves into early adoption trends, comparing the initial uptake of Eli Lilly's oral semaglutide (Foundao) against Novo Nordisk's oral semaglutide (Wegovy's pill), and what these patterns signify for patients and physicians.
6 min read
Oral Wegovy Approval: What the EU's Decision Means for Weight Loss
The European Medicines Agency has recommended approval for oral Wegovy, marking a significant shift in obesity treatment. Explore the implications for patients, efficacy data, and future access.
7 min read
Wegovy and Eye Stroke Risk: What You Need to Know
A recent study has raised questions about a rare but serious eye condition linked to Wegovy. Learn more about ischemic optic neuropathy (ION) and what this research means for patients using GLP-1 medications.
7 min read
The Next Wave of Weight Loss: Understanding Oral GLP-1 Therapy
The landscape of chronic weight management is rapidly evolving beyond injectable GLP-1 medications. New research, including trials for the oral, non-peptide drug orforglipron, suggests a future where highly effective weight loss treatment is as simple as taking a daily pill, potentially overcoming barriers of cost and injection fatigue.
6 min read
GLP-1 Weight Loss Drugs: Eli Lilly's Next-Gen Therapies vs. Novo Nordisk
The race for dominance in the lucrative weight loss drug market is intensifying. While Novo Nordisk's Wegovy has been a pioneer, Eli Lilly is rapidly advancing its pipeline with next-generation therapies poised to challenge the status quo. This article delves into the science, clinical data, and market implications of these groundbreaking treatments.
6 min read
Amazon Stocks Oral Ozempic Pills: Same-Day Delivery & Pricing Guide
Amazon Pharmacy is expanding access to oral GLP-1 medications like Ozempic and Wegovy through kiosks and same-day delivery. Here is everything you need to know about pricing, logistics, and managing your treatment.
7 min read
GLP-1 Medications: Understanding Drug Interactions and Safety
GLP-1 receptor agonists are powerful tools for managing diabetes and obesity, but understanding their potential interactions with other medications is crucial for patient safety and treatment efficacy.
7 min read
GLP-1 Pills for Weight Loss: 8 Key Insights Before You Begin
GLP-1 medications are now available as pills for weight loss, offering a needle-free alternative. This comprehensive guide explores what you need to know before starting, including efficacy, absorption, side effects, and lifestyle considerations.
12 min read
Oral Semaglutide Shows Promise for Pediatric Type 2 Diabetes
Novo Nordisk recently unveiled compelling topline results from the PIONEER TEENS trial, suggesting that oral semaglutide could become the first oral GLP-1 Receptor Agonist (RA) therapy approved for children and adolescents managing Type 2 Diabetes (T2D). This development addresses a significant gap in pediatric endocrinology, offering a potentially more accessible treatment option.
6 min read
Eli Lilly's Oral GLP-1: A Strong Start Amidst Weight Loss Drug Hype
Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.
7 min read
Orforglipron: The New Oral GLP-1 Challenger in Weight Loss
A new daily pill, Orforglipron, is emerging as a significant contender in the weight loss and diabetes management space, offering a potential oral alternative to injectable GLP-1 medications. This article delves into its mechanisms, trial results, and what it means for the future of treatment.
7 min read
New GLP-1 Playbook for Weight Loss: Shots to Pills Shift
Weight loss treatment is evolving with a new GLP-1 playbook: start with weekly injections for rapid results, then transition to convenient pills for maintenance. Eli Lilly's weight-loss tablet and oral Wegovy promise easier adherence, but with trade-offs in effectiveness and strict dosing rules. Doctors highlight the maintenance challenges that make this shift essential.
6 min read
Why Semaglutide Pens Cost More Than Vials: OneSource CEO Explains
Semaglutide injection pens command a higher price than vials primarily due to intricate manufacturing demands in sterile environments and advanced automation, as explained by OneSource Specialty Pharma CEO Neeraj Sharma. With GLP-1 drugs like semaglutide fueling a $34.5 billion market set to double by the mid-2030s, understanding these costs highlights the trade-offs for patient convenience. This guide breaks down the production process and its implications for diabetes and weight management therapies.
5 min read
FDA Approves Foundayo Weight Loss Pill, Igniting GLP-1 Showdown
The FDA has approved Foundayo weight loss pill from Eli Lilly on April 1 (ET), introducing a flexible oral GLP-1 option for adults with obesity or weight-related conditions—no food or water restrictions needed. Trial data shows superior weight loss over Rybelsus, averaging 15-20 pounds vs. 8-11 pounds in diabetes patients. This approval sets up a new showdown in the GLP-1 market dominated by injections like Wegovy and Zepbound.
5 min read
Wegovy Data Challenges Foundayo, Resets Novo Valuation Debate
Novo Nordisk released new cross-trial data showing its oral Wegovy pill delivers greater weight loss than Eli Lilly's newly FDA-approved Foundayo obesity pill. With fewer adverse events and strong patient preference for Wegovy, this first direct comparison challenges Foundayo's profile. The findings arrive amid volatile CPSE:NOVO B stock performance, resetting valuation debates.
5 min read
India's 'Mounjaro Brides': Weight-Loss Injections in Pre-Wedding Prep
In India, 'Mounjaro brides' are using weight-loss injections as part of pre-wedding rituals, driven by intense societal expectations. Clinics like Klarity Skin Clinic offer specialized packages, while doctors report a surge in queries from brides and grooms. This trend highlights both the drugs' popularity and the need for medical supervision.
5 min read
Wegovy Pill Shows Greater Weight Loss Than Foundayo in Novo Study
Novo Nordisk's latest comparison study claims its Wegovy pill delivers superior weight loss compared to Eli Lilly's newly approved Foundayo tablet. The ORION analysis shows a 3.2 percentage point edge for oral semaglutide, plus lower discontinuation rates due to side effects. As oral GLP-1s compete, discover the key findings and implications for patients.
6 min read
FDA Approves Eli Lilly's Foundayo GLP-1 Pill, Stock Jumps 5%
Eli Lilly's shares surged more than 5% following FDA approval of Foundayo, its new once-daily GLP-1 weight-loss pill that can be taken anytime without food restrictions. This oral option intensifies competition with Novo Nordisk's Wegovy and Ozempic, offering real-world convenience for overweight adults. Discover the trial results, comparisons, and implications for obesity treatment.
4 min read
India Issues Guidelines on GLP-1 Drugs Use, Risks, Regulations
The Government of India has issued comprehensive guidelines on GLP-1 drugs, addressing their use for type 2 diabetes and obesity, associated risks, and regulatory measures. With drugs like semaglutide and tirzepatide gaining popularity, authorities warn against unsupervised use due to serious side effects like pancreatitis. Strict surveillance ensures prescriptions only by specialists like endocrinologists.
6 min read
Wegovy's New Subscription Saves Up to $1,200/Year – Not for Everyone
Novo Nordisk has launched a new subscription program for Wegovy, promising up to $1,200 in yearly savings on injections to help patients maintain access to this GLP-1 obesity drug. With plans starting at $249 per month for 12 months, it targets self-pay users facing cost uncertainty. But eligibility limits mean it's not for everyone—here's what you need to know.
4 min read
What Is Orforglipron? New Oral Weight-Loss Pill Trial Results
A groundbreaking phase 3 trial shows orforglipron, a new daily oral weight-loss pill, surpassing oral semaglutide in blood sugar control and weight reduction for type 2 diabetes patients. This small-molecule GLP-1 agonist offers advantages over injectables like Ozempic by eliminating needles and refrigeration needs. However, higher gastrointestinal side effects raise questions about long-term tolerability.
5 min read
FDA Approves Triple Max Dose of Wegovy: 7.2mg Now Available
The FDA just greenlit a groundbreaking higher dose of Wegovy, tripling the previous maximum to 7.2 milligrams for enhanced weight management. Patients saw up to 21% body weight loss, with unique cardiovascular protections. Here's what this means for obesity treatment and access.
5 min read
Alkem Launches Affordable Semaglutide Injection in India at Rs450 Weekly
Alkem Laboratories is revolutionizing GLP-1 access in India with its new semaglutide injection, priced at just Rs450 per week. Branded as Semasize, Obesema, and Hepaglide, this once-weekly therapy targets Type 2 diabetes and chronic weight management. Learn about its approvals, innovative pens, and potential impact on affordable care.
5 min read
Jefferies Reiterates Buy on Eli Lilly Stock on GLP-1 Data
Jefferies has reiterated its Buy rating on Eli Lilly stock with a $1,300 price target, citing encouraging GLP-1 prescription data for the week ending March 13. Oral Wegovy showed strong performance in its 10th launch week, outpacing comparable injectables like Zepbound and Wegovy. Meanwhile, other GLP-1s saw slight declines amid Lilly's promising pipeline.
5 min read
Florida Man Charged for Illegally Selling Off-Brand Ozempic
A St. Johns County man, Adam K. Taylor, is now facing federal misdemeanor charges for misbranding and selling off-brand versions of Ozempic (semaglutide) and other GLP-1 drugs without prescriptions. Operating AKT Labs as 'research purposes only,' he instructed undercover officers on weight loss use. This case highlights dangers of unregulated peptides sourced from China.
5 min read
Semaglutide Generics Set for One-Fourth Price After Patent Expiry
Semaglutide prices in India are poised for a dramatic drop to one-fourth of current levels following patent expiry on March 20. Generics from seven companies like Sun Pharma and Zydus Lifesciences will make Ozempic and Wegovy alternatives more accessible for diabetes and obesity management. Experts highlight improved adherence but warn of misuse risks.
5 min read
Eli Lilly's Employer Connect: Unlocking GLP-1 Demand
Eli Lilly is dominating the GLP-1 market with 25% projected growth in 2026, outpacing Novo Nordisk's decline. Their new Employer Connect platform could unlock massive demand for Zepbound by filling employer coverage gaps. Meanwhile, orforglipron shows superior results over Rybelsus in key trials.
5 min read
Study: Ozempic-Type Drugs Like Semaglutide Can Be Made for $3/Month
A groundbreaking study shows blockbuster drugs like Ozempic and Wegovy could be manufactured at a fraction of their retail cost, potentially revolutionizing access to obesity and diabetes care. Researchers estimate semaglutide production at $3 per month for injectables, compared to hundreds today. This comes amid rising obesity in low-income countries, though experts stress lifestyle factors remain key.
4 min read
GLP-1 Drugs Linked to Skin Pain: New Reports of Dysesthesia & Allodynia
Emerging reports suggest GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) may trigger unusual sensory side effects, including painful skin sensitivity known as dysesthesia and allodynia. A new case series provides critical insights for patients and clinicians.
7 min read
Semaglutide Could Cost as Little as $28/Year by End of 2026
Semaglutide, the powerhouse behind Ozempic and Wegovy, might soon become dramatically more affordable. A recent study reveals generic versions could cost as little as $28 per person-year after patents expire in 2026. This could transform access to treatment for obesity and type 2 diabetes globally.
5 min read
The Himsification of Medicine: Super Bowl Ad & Semaglutide Clash
Hims & Hers made waves with a Super Bowl ad promoting preventive care through tailored prescriptions and peptides for everyday Americans. But announcing compounded oral semaglutide triggered an FDA investigation and a swift lawsuit from Novo Nordisk. The quick settlement highlights battles over GLP-1 access and drug pricing.
4 min read
Meghan Trainor's 'Ozempic Face' in Side-by-Side Pics: Dramatic Changes
Meghan Trainor's striking transformation, showcased in side-by-side photos from 2014 and 2025, has ignited debates on 'Ozempic face' from GLP-1 drugs like Mounjaro. While her defined jawline looks stunning, experts note rapid fat loss can accelerate aging signs like sunken cheeks and wrinkles. Learn the facts amid body positivity backlash.
5 min read
Deutsche Bank Reiterates Buy on Eli Lilly Stock on GLP-1 Growth
Deutsche Bank has reiterated its Buy rating on Eli Lilly stock, highlighting robust GLP-1 prescription growth despite recent dips. With Mounjaro and Zepbound leading, prescriptions rebounded 7% week-over-week, underscoring Lilly's dominance in the diabesity market. Discover the latest data on oral Wegovy and emerging oral GLP-1s like orforglipron.
5 min read
Study Explores Plant-Based Platform for Oral GLP-1 Therapies
A pioneering study led by Henry Daniell at Penn Dental Medicine has engineered lettuce chloroplasts to produce functional exenatide and lixisenatide, offering a plant-based path to oral GLP-1 therapies. This approach addresses key barriers like stomach degradation and high costs, potentially transforming diabetes and obesity treatment. Patients may soon swap weekly injections for simple lettuce-based pills.
6 min read
Joan Collins, 92, Rejects Ozempic Over 'Disastrous Faces' and Needles
At 92, actress Joan Collins declares she'd 'never dream' of using Ozempic, citing 'too many disastrous faces' and her aversion to needles. This sparks discussion as Kelly Osbourne confronts cruel commentary on her look at the Brit Awards. Learn the medical context behind these celebrity views on GLP-1 drugs.
5 min read
Zydus' ZYOG1: Oral GLP-1 Ahead of Ozempic by 15 Years
Fifteen years before Ozempic sparked the GLP-1 revolution, Zydus Lifesciences in India developed ZYOG1, a promising oral GLP-1 agonist. Showing preclinical benefits for glucose control, weight loss, and a clean safety profile, it earned phase I trial approval in 2010—but was shelved amid high costs. This untold story highlights India's early edge in peptide therapy.
5 min read
SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds
New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.
6 min read
Novo Nordisk Stock Erases Wegovy Gains After CagriSema Miss
Novo Nordisk's stock has erased the last of its Wegovy-driven gains in a brutal week, down 21% after next-gen obesity drug CagriSema underperformed rivals. Despite 20.2% weight loss in trials, analysts downgrade amid patent cliffs and competition from Eli Lilly's tirzepatide. The company's pivot to oral Wegovy offers hope, but diversification pressures mount.
5 min read
Eli Lilly's Orforglipron: More Effective GLP-1 Pill for Weight Loss?
Eli Lilly's investigational GLP-1 pill, orforglipron, demonstrated greater weight loss and blood sugar control than oral semaglutide in a major phase 3 trial for type 2 diabetes. Patients lost 6-8% body weight compared to 4-5%, though with higher GI side effects. This could signal a shift toward more effective oral therapies.
6 min read
Beyond the Scale: GLP-1 Medications' Impact on Body and Mind
Alexis Ioane hesitated before starting tirzepatide, a GLP-1 medication, but two months in, she's shed pounds, gained energy for her kids, and cleared her mind. While GLP-1s like Ozempic and Wegovy promise transformative weight loss, experts caution about mental health effects. Discover the full story on body and mind impacts.
6 min read
Zydus Launches Semaglutide in Reusable Pen After Patent Expiry: Prices to Fall
Zydus Lifesciences is set to revolutionize semaglutide access in India with a reusable adjustable pen device after the patent expires on March 20. Brands like SEMAGLYN™, MASHEMA™, and ALTERMET™ promise easier dosing and lower prices around ₹3,500-4,000 per month. This move could expand GLP-1 therapy for Type 2 diabetes and obesity amid rising demand.
5 min read
Animal Study Reveals Concerns for Semaglutide Pills
Researchers have identified potential concerns with oral semaglutide after an animal study showed biological changes from non-active formulation components. Unlike injections such as Ozempic or Wegovy, pills use excipients and absorption enhancers that may introduce unintended effects. This early warning calls for further human evaluation.
4 min read
Can GLP-1 Drugs Power Healthify's Coaching Future? Semaglutide Shift
Healthify, built on coaching, stands at the cusp of transformation as GLP-1 drugs like semaglutide prepare for patent expiry in India by 2026. Deloitte India's Srikanth Mahadevan forecasts 120,000-150,000 incremental patients in diabetes and weight management. This shift could make premium therapies accessible, fueling coaching platforms' growth.
5 min read
Study Flags Gut Risks from SNAC in Oral Weight-Loss Pills
A groundbreaking study from Adelaide University is raising questions about SNAC, the ingredient making oral weight-loss drugs like semaglutide tablets viable. In a 21-day animal model, repeated SNAC exposure linked to lower beneficial gut bacteria, reduced protective compounds, and elevated inflammation markers. As tablet versions gain popularity, experts call for more research on this component's full impact.
6 min read
Hims & Hers GLP-1 Pill Launch Backfires, Fuels Compounder Crackdown
Hims & Hers aimed to disrupt the GLP-1 market with a cheap oral semaglutide pill, but faced swift FDA backlash and a patent lawsuit from Novo Nordisk. The retreat highlights regulatory risks for compounders as branded supplies stabilize. This analysis reveals challenges in oral GLP-1 production and future paths for telehealth weight loss offerings.
6 min read
Novo Nordisk to Meet US Wegovy Pill Demand First, CEO Doustdar Says
Novo Nordisk is prioritizing the US market for its popular Wegovy pill to prevent shortages like those seen with injectable semaglutide. CEO Mike Doustdar emphasized a country-by-country rollout strategy amid legal battles against compounders and competition from Eli Lilly. With 246,000 US users already on the oral obesity drug, supply stability is key.
5 min read
Lilly's $1.5B Orforglipron Inventory Grows Ahead of FDA Obesity Nod
Eli Lilly is stockpiling $1.5 billion worth of its oral obesity drug orforglipron to avoid the supply shortages that hampered early GLP-1 launches. With an expected FDA decision on April 10, the company aims for a swift global rollout against Novo Nordisk's Wegovy pill. This strategic move signals big changes in accessible weight loss therapy.
5 min read
How Restaurants Are Adapting to Rising GLP-1 Usage Like Ozempic
Popular GLP-1 drugs like Ozempic and Wegovy are curbing appetites, prompting restaurants to adapt with specialized menus. Cuba Libre's Barry Gutin explains their high-protein, smaller-portion offerings designed with a doctor's input. This trend signals a lasting change in dining habits.
5 min read
Knockoff GLP-1 Market Still the Wild West: Hims Fallout
Telehealth firm Hims & Hers sparked chaos by launching a cheap compounded Wegovy pill, only to yank it days later amid FDA crackdowns and a Novo Nordisk lawsuit. This incident highlights the ongoing Wild West in the knockoff GLP-1 market. Despite resolved shortages for Wegovy and Zepbound, unregulated compounded drugs remain widely available.
5 min read